Interleukin 6 Antagonists in Severe COVID-19 Disease: Cardiovascular and Respiratory Outcomes

Area of Science:

• Immunology
• Virology
• Critical Care Medicine

Background:

• Severe COVID-19 is linked to cytokine release syndrome (CRS), characterized by elevated inflammatory cytokines.
• The host immune response, while protective, can cause significant tissue damage, sepsis, and organ failure in severe cases.

Purpose of the Study:

• To review the role of interleukin 6 (IL-6) in COVID-19 pathogenesis.
• To assess the efficacy of IL-6 inhibitors in clinical trials for treating COVID-19.

Main Methods:

• Review of existing literature and clinical trial data on IL-6 inhibitors in COVID-19.
• Analysis of studies evaluating IL-6 inhibitors as immunomodulators in severe COVID-19 patients.

Main Results:

• Clinical trials on IL-6 inhibitors in COVID-19 have yielded mixed results.
• A general consensus supports the use of IL-6 inhibitors in severely ill COVID-19 patients, irrespective of specific outcomes when used with dexamethasone.

Conclusions:

• IL-6 inhibitors represent a potential strategy to regulate the inflammatory cascade in severe COVID-19.
• Despite some conflicting data, IL-6 inhibitors are considered beneficial for managing critically ill COVID-19 patients experiencing cytokine storms.